Searched for
CLARITHROMYCIN
Govt revises prices of 71 medicines, including those for diabetes and infections: Check new ratesThe National Pharmaceutical Pricing Authority (NPPA) has revised the prices of 71 essential drug formulations, encompassing treatments for ...- Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in IndiaSun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug...
- Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in IndiaSun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in...
- India resurgence fund in talks to acquire Ind-Swift's API businessEarlier in July 2021, Ind-Swift Laboratories had agreed to sell its API business to PI Industries on a slump sale basis, for ₹1,530 crore. ...
- Alembic gets USFDA approval to market Clarithromycin tablets in AmericaAlembic's product is therapeutically equivalent to AbbVie Inc's Biaxin Filmtab Tablets, which is antimicrobial indicated to treat mild to m...
- Lancet study finds no benefit for hydroxychloroquine in COVID-19 patientsThe scientists said these drugs should not be used to treat COVID-19 patients outside of clinical trials until results from randomised clin...
- Teva-Allergan deal may divest products worth $600 millionAs Israeli drugmaker Teva readies to acquire Allergan as part of its recent $40.5-billion deal, a large bounty of products is expected to b...
- Wockhardt recalls over 50 lakh bottles of various drugs in USAs per the information available on the USFDA, Wockhardt is recalling the drugs for current good manufacturing practice (CGMP) deviations.
- Wockhardt recalls over 1.62 lakh cartons of drugs in USs per the information available on the US Food and Drug Administration's (USFDA) website, Mumbai-based Wockhardt is recalling the drugs for...
- Sensex falls over 150 points, Sun TV plunges 28%, Eros gains 20%; top betsThe S&P BSE Sensex opened the day at 26,810.98, up 42.49 points. The broader 50-share Nifty opened the session at 8,114.7, down 15.95 point...
- Twelve stocks in focus in Monday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Two drugs manufactured by Wockhardt recalled in the USAccording to information on the US Food and Drug Administration (USFDA) website, 166 bottles of Captopril tablets of 50 mg strength are bei...
- Ind Swift get USFDA nod for five active pharmaceutical ingredientsInd Swift Laboratories today said it has received US health regulator's approval to sell five active pharmaceutical ingredients.
- Ind Swift Lab gets Australia's nod for its Dera Bassi plantDrug firm Ind Swift said it has received approval from the Australian health regulator to make seven active pharmaceutical ingredients.
- US FDA blocks imports from Ranbaxy for poor qualityFDA move does not end US sales by Ranbaxy. The factories with defects are in Dewas and Paonta Sahib. The Top 10 food myths revealed | Bewar...
- Ranbaxy faces adulteration charges in USUS department of justice has said there was evidence to suggest that Ranbaxy used active pharmaceutical ingredients from unapproved sources...
- Pharma cos set sights on JapanAs pricing pressure intensifies in the US generics market, Indian pharma majors are planning rapid inroads into Japan, which is the worlds ...
- Ranbaxy recieves US approval for anti-bacterial drugUS Food and Drug Administration's has given the approval to manufacture and market anti-bacterial drug oral Clarithromycin in multiple stre...
- Ranbaxy gets USFDA nod for Clarithromycin oral suspensionRanbaxy Laboratories has received final approval from the US Food and Drug Administration to manufacture and market Clarithromycin for oral...
- Ranbaxy gets FDA nod for clarithromycinRanbaxy is the first company to have been granted a generic approval for the oral suspension form along with clarithromycin tablets.
Load More
